ストックスクリーナーアプリを入手
310.67
20.88%
53.67
アフターアワーズ：
312.00
1.33
+0.43%
前日終値:
$257.00
開ける：
$293.03
24時間の取引高:
3.21M
Relative Volume:
3.85
時価総額：
$18.08B
収益：
$1.98B
当期純損益:
$420.90M
株価収益率:
53.20
EPS:
5.84
ネットキャッシュフロー:
$218.20M
1週間 パフォーマンス:
+20.88%
1か月 パフォーマンス:
+17.36%
6か月 パフォーマンス:
+15.92%
1年 パフォーマンス:
+75.00%
1日の値動き範囲:
$293.03
$312.16
1週間の範囲:
$252.88
$312.16
52週間の値動き範囲:
$160.19
$312.16
Insulet Corporation Stock (PODD) Company Profile
PODD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
310.67 | 18.08B | 1.98B | 420.90M | 218.20M | 5.84 |
|
ABT
Abbott Laboratories
|
133.24 | 231.09B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
102.86 | 155.24B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.92 | 144.54B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.48 | 108.82B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.68 | 44.31B | 5.54B | 4.18B | 623.10M | 7.00 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-11-06 | 開始されました | Bernstein | Outperform |
| 2024-05-30 | 開始されました | Redburn Atlantic | Buy |
| 2024-05-07 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-21 | アップグレード | Citigroup | Neutral → Buy |
| 2023-08-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 開始されました | Wolfe Research | Peer Perform |
| 2022-11-04 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-02-02 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-07-28 | 開始されました | Wells Fargo | Overweight |
| 2020-04-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 開始されました | BofA/Merrill | Neutral |
| 2020-03-31 | ダウングレード | Berenberg | Buy → Hold |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-12-10 | 開始されました | CFRA | Sell |
| 2019-10-23 | 開始されました | Stifel | Hold |
| 2019-10-18 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-10-04 | ダウングレード | UBS | Buy → Neutral |
| 2019-10-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-06-10 | ダウングレード | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-04-20 | 開始されました | Berenberg | Buy |
| 2018-02-22 | 繰り返されました | Barclays | Overweight |
| 2018-01-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 開始されました | Barclays | Overweight |
すべてを表示
Insulet Corporation (PODD) 最新ニュース
Insulet Corporation (NASDAQ:PODD) Q1 2025 Earnings Call Transcript - Insider Monkey
Insulet (PODD) Sees Price Target Boost Amid Strong Sales Performance | PODD Stock News - GuruFocus
BTIG raises Insulet stock price target to $330, maintains Buy rating - Investing.com Nigeria
Insulet’s Earnings Call Reveals Strong Growth and Expansion - TipRanks
Piper Sandler maintains Overweight rating on Insulet stock By Investing.com - Investing.com Canada
Insulet Seeks $30M In Atty Fees, Costs After Trade Secret Win - Law360
U.S. Indexes Ended Friday Mixed As Insulet Led, Affirm Holdings Lagged - Barron's
New Insulet CEO Ashley McEvoy sets priorities - MedTech Dive
Sector Update: Health Care - marketscreener.com
Canaccord raises Insulet stock target to $331, maintains buy rating - Investing.com
Piper Sandler maintains Overweight rating on Insulet stock - Investing.com
Why Insulet (PODD) Stock Is Trading Up Today - Yahoo Finance
Insulet Stock Soars to Lead S&P 500 Gainers Friday - Investopedia
Insulet Q1 beat, Sweetgreen sinks on outlook, Wolfspeed drops - Yahoo Finance
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday By Investing.com - Investing.com South Africa
Tesla, Insulet Surge Among Market Cap Stock Movers on Friday - Investing.com Australia
Insulet (PODD) Price Target Raised by Oppenheimer Analyst | PODD Stock News - GuruFocus
Insulet (NasdaqGS:PODD) Announces $125M Buyback, Raises Revenue Guidance For 2025 - Yahoo Finance
Top Stock Movers Now: Tesla, Monster Beverage, Insulet, and More - Investopedia
Insulet Posts Strong Q1 Results, Raises Forecasts On Momentum In US And Abroad - Benzinga
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers By Investing.com - Investing.com Nigeria
Trade Desk, Insulet Surge in Friday’s Market Cap Stock Movers - Investing.com Australia
Insulet Stock Is the Top S&P 500 Performer Today. Here’s Why. - MSN
Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday - Benzinga
Piper Sandler on Insulet Corporation (PODD): 'Strong Update Across the Board' - StreetInsider
Canaccord raises Insulet stock target to $331, maintains buy rating By Investing.com - Investing.com India
BTIG Boosts Price Target for Insulet (PODD) After Strong Q1 Results | PODD Stock News - GuruFocus
Baird Adjusts Price Target on Insulet to $350 From $325, Maintains Outperform Rating - marketscreener.com
Insulet Corporation Exceeds Q1 CY2025 Revenue ExpectationsNews and Statistics - IndexBox
Insulet Corporation (PODD) PT Raised to $331 at Canaccord Genuity - StreetInsider
Insulet Corporation (PODD) PT Raised to $330 at BTIG - StreetInsider
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com Nigeria
Insulet Corp (PODD) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion - GuruFocus
Insulet Corporation Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Insulet beats Q1 2025 forecasts, stock surges - Investing.com Australia
Insulet requests $30 million in attorneys fees after EOFlow trade secret injunction - MLex
Insulet’s (NASDAQ:PODD) Q1: Strong Sales, Stock Soars - Yahoo Finance
Insulet: Q1 Earnings Snapshot - MySA
Insulet's Strong Profit And Innovation Propel Shares Higher - Finimize
Insulet (PODD) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insulet Q4 2024 slides: revenue tops $2.1B, margins expand as Type 2 diabetes push begins - Investing.com
Insulet (PODD) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
Insulet Corp (PODD) Q1 2025 Earnings: Revenue Surges to $569M, Beating Estimates, EPS Falls Short at $0.50 - GuruFocus
Insulet Jumps After Beating Quarterly Forecasts, Raising 2025 Expectations - MSN
Insulet earnings beat by $0.23, revenue topped estimates By Investing.com - Investing.com South Africa
Insulet beats quarterly profit estimates on insulin pump demand - marketscreener.com
Insulet earnings beat by $0.23, revenue topped estimates - Investing.com Canada
Insulet Q1 Earnings Fall, Revenue Rises - marketscreener.com
Insulet (PODD) Reports Strong Q1 Revenue Beating Estimates | PODD Stock News - GuruFocus
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1) - Business Wire
Insulet Pursues EOFlow's Finances After $60M Ruling - Law360
Insulet Corporation (PODD) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
0.79%
大文字化:
|
ボリューム (24 時間):